Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment

被引：20

作者：

Bose, Gauruv ^{[1
,2
]}

Freedman, Mark S. ^{[1
,2
]}

机构：

[1] Ottawa Hosp, Res Inst, Div Neurol, Gen Campus,501 Smyth Rd,Box 601, Ottawa, ON K1H 8L6, Canada

[2] Univ Ottawa, Dept Med, Ottawa, ON, Canada

来源：

MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 05期

关键词：

Multiple sclerosis; precision medicine; patient-centered care; neurology; STEM-CELL TRANSPLANTATION; DISABILITY PROGRESSION; CLADRIBINE TABLETS; DISEASE; OCRELIZUMAB; ALEMTUZUMAB; PLACEBO; PREDICT; LESIONS; MS;

D O I：

10.1177/1352458519887324

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system (CNS), affecting patients of all ages, causing neurologic disability if inadequately treated. Some patients have a relatively benign disease course without significant disability after decades, while a more aggressive course ensues in others and disability progression occurs after only several years. Certain risk factors confer a higher chance of a patient having aggressive MS. Currently over 15 disease-modifying treatments (DMTs) are approved for MS with different efficacy and safety profiles. Deciding which DMT to use in a specific patient requires a careful analysis of a patient's disease course for high-risk factors for early progression, consideration of the efficacy and safety profile for potential therapy, as well as understanding of a patient's lifestyle and expectations. The integration of these factors is the art of precision medicine, a necessary practice in the treatment of patients with MS.

引用

页码：540 / 547

页数：8

共 35 条

[1] Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis [J].

Agosta, Federica ;

Rovaris, Marco ;

Pagani, Elisabetta ;

Sormani, Maria Pia ;

Comi, Giancarlo ;

Filippi, Massimo .

BRAIN, 2006, 129 :2620-2627

[2] Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial [J].

Atkins, Harold L. ;

Bowman, Marjorie ;

Allan, David ;

Anstee, Grizel ;

Arnold, Douglas L. ;

Bar-Or, Amit ;

Bence-Bruckler, Isabelle ;

Birch, Paul ;

Bredeson, Christopher ;

Chen, Jacqueline ;

Fergusson, Dean ;

Halpenny, Mike ;

Hamelin, Linda ;

Huebsch, Lothar ;

Hutton, Brian ;

Laneuville, Pierre ;

Lapierre, Yves ;

Lee, Hyunwoo ;

Martin, Lisa ;

McDiarmid, Sheryl ;

O'Connor, Paul ;

Ramsay, Timothy ;

Sabloff, Mitchell ;

Walker, Lisa ;

Freedman, Mark S. .

LANCET, 2016, 388 (10044) :576-585

[3] Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score [J].

Bergamaschi, Roberto ;

Quaglini, Silvana ;

Trojano, Maria ;

Amato, Maria Pia ;

Tavazzi, Eleonora ;

Paolicelli, Damiano ;

Zipoli, Valentina ;

Romani, Alfredo ;

Fuiani, Aurora ;

Portaccio, Emilio ;

Berzuini, Carlo ;

Montomoli, Cristina ;

Bastianello, Stefano ;

Cosi, Vittorio .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2007, 78 (07) :757-759

[4] Immunomodulatory therapies delay disease progression in multiple sclerosis [J].

Bergamaschi, Roberto ;

Quaglini, Silvana ;

Tavazzi, Eleonora ;

Amato, Maria Pia ;

Paolicelli, Damiano ;

Zipoli, Valentina ;

Romani, Alfredo ;

Tortorella, Carla ;

Portaccio, Emilio ;

D'Onghia, Mariangela ;

Garberi, Francesca ;

Bargiggia, Valeria ;

Trojano, Maria .

MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (13) :1732-1740

[5] Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome [J].

Brownlee, W. J. ;

Altmann, D. R. ;

Da Mota, P. Alves ;

Swanton, J. K. ;

Miszkiel, K. A. ;

Wheeler-Kingshott, C. A. M. Gandini ;

Ciccarelli, O. ;

Miller, D. H. .

MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (05) :665-674

[6] Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis [J].

Chitnis, Tanuja ;

Gonzalez, Cindy ;

Healy, Brian C. ;

Saxena, Shrishti ;

Rosso, Mattia ;

Barro, Christian ;

Michalak, Zuzanna ;

Paul, Anu ;

Kivisakk, Pia ;

Diaz-Cruz, Camilo ;

Sattarnezhad, Neda ;

Pierre, Isabelle V. ;

Glanz, Bonnie I. ;

Tomic, Davorka ;

Kropshofer, Harald ;

Haring, Dieter ;

Leppert, David ;

Kappos, Ludwig ;

Bakshi, Rohit ;

Weiner, Howard L. ;

Kuhle, Jens .

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2018, 5 (12) :1478-1491

[7] Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial [J].

Cohen, Jeffrey A. ;

Coles, Alasdair J. ;

Arnold, Douglas L. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Fisher, Elizabeth ;

Brinar, Vesna V. ;

Giovannoni, Gavin ;

Stojanovic, Miroslav ;

Ertik, Bella I. ;

Lake, Stephen L. ;

Margolin, David H. ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1819-1828

[8] Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial [J].

Coles, Alasdair J. ;

Twyman, Cary L. ;

Arnold, Douglas L. ;

Cohen, Jeffrey A. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Miller, Tamara ;

Fisher, Elizabeth ;

Sandbrink, Rupert ;

Lake, Stephen L. ;

Margolin, David H. ;

Oyuela, Pedro ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1829-1839

[9]

Comi G, 2018, THER ADV NEUROL DISO, V11, P1, DOI [10.1177/1756285617753365, 10.1177/1756285618753365]

[10] Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course [J].

Conway, Devon S. ;

Thompson, Nicolas R. ;

Cohen, Jeffrey A. .

MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (02) :277-285

← 1 2 3 4 →